ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 248

Synovial Fluid Leptin Level Is Associated with Residual Pain and Functional Disability One Year After Total Joint Arthroplasty

Anne Lübbeke1, Gabor J. Puskas1, Axel Finckh2, Domizio Suva1, Sylvette Bas3, Cem Gabay3, Daniel Fritschy1 and Pierre Hoffmeyer1, 1Orthopaedic Surgery, Geneva University Hospitals, Geneva, Switzerland, 2Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland, 3Rheumatology, Geneva University Hospitals, Geneva, Switzerland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Osteoarthritis, pain and total joint replacement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:

 

A sizeable number of patients continue to suffer from pain, functional disability and reduced quality of life after total joint arthroplasty (TJA). The etiology of post-TJA pain is not well established and the presence of chronic pain of neuropathic origin has been suggested.

Leptin has been identified as a mediator of the immuno-inflammatory response in osteoarthritis (OA), and its pro-inflammatory functions could explain its role in peripheral pain sensitization. We previously demonstrated that high synovial fluid (SF) leptin concentrations correlate with increased preoperative pain in hip and knee OA patients. In addition, animal models have suggested the involvement of leptin in the pathogenesis of pain at the spinal level and in the development of neuropathic pain.

Our objective was to assess pain, function, patient satisfaction and general health in patients undergoing TJA according to SF leptin concentration.

Methods:

 

Prospective cohort study of patients with primary OA undergoing total hip or knee arthroplasty between January and December 2010. On the day of intervention, SF was sampled and leptin concentrations were assessed using an ELISA kit. Exposure was SF leptin concentration (≤19.6 ng/ml vs. >19.6 ng/ml= highest quartile). Outcomes were: joint pain, function and general health measured pre- and at 1 year postoperative with WOMAC, VAS for pain, and SF-12, and patient satisfaction at 1 year measured on 5-item Likert scale.

Results:

 

167 TJAs were included, 88 total hip and 79 total knee arthroplasties. Mean age was 72 years, mean BMI 28 kg/m², 58% were women. High intra-operative SF leptin concentrations (>19.6 ng/ml) were found in 39 (23.4%) joints. Compared to leptin levels <19.6 ng/ml their presence was associated with significantly higher pain levels on both WOMAC and VAS pain scales, with lower function and worse physical and mental health scores both pre- and 1 year postoperative (effect sizes ranging from 0.4 to 0.7) and with lower satisfaction (see Table). Residual pain of ≥5 on the VAS was present in 33% of TJAs with high leptin concentration compared to 13% in the other group (RR 2.5, 95% CI 1.3; 4.7). The degree of improvement in all domains (difference pre- to postoperative) was not significantly modified by SF leptin levels.

Conclusion:

High intra-articular leptin were strongly associated with more residual pain and functional disability 1 year after arthroplasty. However, the degree of improvement was independent of leptin concentration. With respect to pain these results lend support to the hypothesis that high intra-articular leptin levels could favor spinal pain sensitization and the development of neuropathic pain earlier in the disease process.

Table 1. Preoperative  and 1-year postoperative assessment of pain, function and general health according to leptin concentration

 

Leptin 1-3rd quartile

≤ 19.6 ng/ml

n

Leptin 4th quartile

> 19.6 ng/ml

n

4th vs. 1-3rd quartile

Unadjusted mean difference (95% CI)

4th vs. 1-3rd quartile

Adjusted mean difference (95% CI)*

WOMAC pain, mean (SD)

 

116

 

36

 

 

      Preoperative

42.2 (±18.3)

 

32.5 (±15.5)

 

9.7 (3.1; 16.4)

9.1 (2.6; 15.5)

      At 1 year

71.8 (±24.1)

 

61.5 (±21.1)

 

10.2 (1.4; 19.1)

9.8 (0.8; 18.8)

      Difference

29.5 (±23.8)

 

29.0 (±21.2)

 

0.5 (-8.2; 9.2)

0.7 (-8.2; 9.6)

 

 

 

 

 

 

 

WOMAC function, mean (SD)

 

116

 

36

 

 

      Preoperative

44.6 (±19.9)

 

37.6 (±15.4)

 

7.0 (0.8; 13.3)

7.4 (0.5; 14.2)

      At 1 year

71.1 (±24.4)

 

62.5 (±20.4)

 

8.6 (-0.3; 17.5)

8.7 (-0.3; 17.8)

      Difference

26.5 (±25.2)

 

24.9 (±23.1)

 

1.6 (-7.7; 10.9)

1.3 (-8.1; 10.8)

 

 

 

 

 

 

 

VAS pain, mean (SD)

 

122

 

37

 

 

      Preoperative

5.8 (±1.8)

 

6.5 (±1.7)

 

0.7 (0; 1.3)

0.6 (0; 1.2)

      At 1 year

1.9 (±2.1)

 

3.3 (±2.4)

 

1.4 (0.5; 2.1)

1.2 (0.4; 2.0)

      Difference

3.9 (±2.3)

 

3.2 (±2.6)

 

0.7 (-0.2; 1.6)

0.6 (-0.3; 1.5)

 

 

 

 

 

 

 

SF-12 physical component, mean (SD)

 

112

 

34

 

 

      Preoperative

35.7 (±8.4)

 

32.0 (±7.1)

 

3.7 (0.5; 6.8)

4.0 (0.8; 7.1)

      At 1 year

42.3 (±9.4)

 

36.4 (±9.2)

 

5.9 (2.3; 9.5)

5.9 (2.2; 9.5)

      Difference

6.6 (±9.9)

 

4.4 (±8.8)

 

2.2 (-1.5; 6.0)

1.9 (-1.9; 5.7)

 

 

 

 

 

 

 

SF-12 mental component, mean (SD)

 

112

 

34

 

 

      Preoperative

44.8 (±11.0)

 

39.3 (±11.0)

 

5.5 (1.2; 9.8)

5.8 (1.5; 9.9)

      At 1 year

47.5 (±10.1)

 

41.0 (±9.7)

 

6.5 (2.7; 10.4)

6.7 (2.9: 10.5)

      Difference

2.8 (±11.1)

 

1.7 (±11.3)

 

1.1 (-3.3.; 5.4)

1.0 (-3.4; 5.4)

 

 

 

 

 

 

 

Satisfaction (%)

 

126

 

39

 

 

    Very satisfied

82 (64.1)

 

12(30.8)

 

 

 

    Satisfied

20 (15.6)

 

18 (46.2)

 

 

 

<>    Somewhat satisfied

12 (9.4)

 

5 (12.8)

 

 

 

<>    Dissatisfied

12 (9.4)

 

4 (10.3)

 

p=0.002

 

 

 

 

 

 

 

 

*Adjusted for age, ASA score, OA site (hip vs. knee) and Charnley disability grade with use of multivariable linear regression


Disclosure:

A. Lübbeke,
None;

G. J. Puskas,
None;

A. Finckh,
None;

D. Suva,
None;

S. Bas,
None;

C. Gabay,
None;

D. Fritschy,
None;

P. Hoffmeyer,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synovial-fluid-leptin-level-is-associated-with-residual-pain-and-functional-disability-one-year-after-total-joint-arthroplasty/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology